This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Update on the Evolving Treatment Landscape for Metastatic Breast Cancer: The Impact of Novel Microtubule Targeted Agents on Survival and Quality of Life

Update on the Evolving Treatment Landscape for Metastatic Breast Cancer: The Impact of Novel Microtubule Targeted Agents on Survival and Quality of Life

Format

Webcast

Time to Complete

Up to 2.5 hours

Released

June 26, 2015

Expires

June 26, 2016
Add to Queue


Maximum Credits

2.50 / AMA PRA Category 1 Credit(s)TM
2.50 / CE for Nurses

Accredited Provider

This activity is jointly provided by Global Education Group and Educational Concepts in Medicine.

Commercial Supporter

This activity is supported by an educational grant from Eisai.

Program Description

Breast cancer represents a significant public health burden—it is the most common cancer in women and the second most common cause of death in women in the United States. Advances in the diagnosis and management of breast cancer have resulted in improved survival. The introduction of novel therapies for the treatment of both newly diagnosed and metastatic breast cancer (MBC) has contributed to this decline.

Although the treatment of MBC has improved dramatically over the past decades, resistance to chemotherapy still presents a significant obstacle in patient care. Anthracyclines and, more recently, taxanes have been the standard therapy in patients with recurrent MBC. Because of the increase in use of anthracyclines and taxanes as therapy for early stage breast cancer, many patients’ tumors are resistant to these agents by the time the tumor becomes metastatic. Additionally, even when these treatment options can be used in the MBC setting, treatment failure occurs in most cases. As a result, the overall survival rates when using taxanes and/or anthracyclines are relatively low.

Recently, newer agents, such as the microtubule-targeting eribulin and ixabepilone, have shown improved overall survival with less toxicity and improved quality of life. However, not all healthcare providers are knowledgeable about newer treatment options, or when to use them. An analysis of about 2000 patient cases, presented at the 2013 San Antonio Breast Cancer Symposium, showed that community practitioners are recommending newly approved agents substantially less frequently than are expert oncologists.

Join our experts as they discuss advances in breast cancer research, detection, and treatment, as well as the various professional cancer guidelines available and how to implement management recommendations in clinical practice.

Intended Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, surgeons, oncology nurses, OB/GYNs, and other healthcare professionals who treat patients with metastatic breast cancer.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Identify the nuances of managing metastatic breast cancer (MBC), including the application of recent findings regarding prognostic and predictive markers to better select more targeted therapies
  • Review the spectrum of chemotherapeutic agents used in the treatment of MBC, comparing and contrasting distinct modes of action, as well as data on safety, efficacy, adverse events, and clinical application in diverse clinical situations
  • Discuss the pharmacologic properties and survival prolongation data with novel treatments, including non-taxane microtubule dynamics inhibitors
  • Select sequential versus combination treatment strategies based on patient symptoms, rate of disease progression, and comorbidities
  • Implement individualized therapy for MBC patients by considering current guidelines, emerging clinical trial data, expert opinion, and recommendations, as well as specific patient and tumor characteristics

Conflict Of Interest Disclosure Policy

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty

Kerin Adelson, MD
Assistant Professor of Medicine (Medical Oncology)
Chief Quality Officer
Smilow Cancer Hospital
Yale Cancer Center
New Haven, CT

Dr. Adelson discloses that she is on the speakers bureau for Genomic Health.

Peter Kaufman, MD
Associate Professor of Medicine
Breast Oncology Program Norris Cotton Cancer Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH

Dr. Kaufman discloses that he is a consultant for Celgene, Genentech, and Amgen. He also provides grant/research support for Eisai, Amgen, and Genentech.

Andrew D. Seidman, MD
Attending Physician
Breast Cancer Medicine Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Dr. Seidman discloses that he is a consultant for Eisai and receives honoraria from Celgene and Eisai. He is also on the speakers bureau for Celgene and Eisai.

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Global Clinical Reviewers: Ashley Marostica, RN, MSN, Amanda Glazar, PhD, and Andrea Funk have no real or apparent conflicts of interest to report.

ECM: Patrick J. Crowley, MBA, Dina Kouveliotes, Jodi Andrews, Jo-Ann Angelucci, and Susan Scher, MD, have no real or apparent conflicts of interest to report.

Credit

2.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Educational Concepts in Medicine. Global is accredited by the ACCME to provide continuing medical education for physicians.

Note: This CME/CE activity complies with all requirements of the federal Physician Payments Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Designation Statement

Global Education Group designates this enduring material for a maximum of 2.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

2.50

Type

CE for Nurses

Accreditation Statement

Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

This educational activity for up to 2.50 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or inquire@globaleducationgroup.com.

If you have any other questions relating to your certificate or other issues with the activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue